我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

阿托伐他汀钙对冠心病患者胆红素水平的影响及胆红素水平变化与CRP、血尿酸的相关分析(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第2期
页码:
184-187,191
栏目:
临床研究
出版日期:
2016-11-25

文章信息/Info

Title:
Relationship between bilirubin level and C-reactive protein and serum uric acid after using atorvastatin
作者:
任彬诚1; 高 星2; 史小飞1; 袁 媛2; 叶 菁2; 冯旭阳1
（第四军医大学西京医院：1.心血管内科，2.病理科，陕西 西安 710032）
Author(s):
REN Bin-cheng1;  GAO Xing2;  SHI Xiao-fei1;  YUAN Yuan2;  YE Jing2;  FENG Xu-yang1
(1.Department of Cardiology, 2.Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
阿托伐他汀钙; 冠状动脉疾病; 胆红素; C反应蛋白
Keywords:
atorvastatin-calcium;  bilirubin;  coronary disease;  C-reactive protein
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 探讨初次服用不同剂量阿托伐他汀钙的冠心病患者血清胆红素水平变化,并将胆红素水平变化同C反应蛋白(CRP)、血尿酸进行相关性分析。方法 回顾性分析心脏内科初诊冠心病患者276例, 根据冠心病患者实际服用阿托伐他汀钙的剂量，分为20 mg/d组(158例)和40 mg/d组(118例)。收集服药前后临床资料，血清胆红素、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、CRP、血清尿酸水平进行对比分析，同时观察阿托伐他汀钙治疗1个月后上述指标的变化水平,并进行相关性分析。结果 两不同剂量组服药后与服药前相比，血清总胆红素水平及直接胆红素水平均呈显著性升高（P<0.05），间接胆红素水平前后无明显差异。CRP水平与血清尿酸水平明显降低（P<0.05）。两不同剂量组间比较，40 mg/d组患者血清总胆红素〔服药前：(10.3±2.0) μmol/L；服药后：(13.7±2.2) μmol/L〕、直接胆红素〔服药前：(3.0±1.1) μmol/L；服药后：(4.6±1.3) μmol/L〕升高更显著（P<0.05），但间接胆红素水平未发生明显变化。同时40 mg/d组CRP及血清尿酸水平较20 mg/d组降低水平更明显（P<0.05）。直接胆红素变化与患者CRP、血清尿酸水平均呈负相关性。结论 阿托伐他汀钙治疗冠心病可促使血清胆红素水平升高，同时降低CRP和血清尿素水平；且高剂量较低剂量作用更显著。血清胆红素水平的升高同CRP降低、血尿酸水平降低呈负相关。
Abstract:
AIM To investigate the relationship of the serum bilirubin level and related risk factors of coronary atherosclerosis in patients with coronary heart disease (CHD) using atorvastatin for the first time. METHODS According to inclusion and exclusion criteria, 276 patients who were first diagnosed with CHD were screened and randomly divided into 20 mg/day (158) and 40 mg/day (118) treatment groups. Changes of the above indexes were observed and its correlation was analyzed after 1 month treatment with atorvastatin calcium. Serum bilirubin, C-reactive protein (CRP), serum uric acid (SUA) level and baseline data were detected. RESULTS Whether using 20 mg/day or 40 mg/day of atorvastatin calcium, serum total bilirubin and direct bilirubin levels were significantly increased (P<0.05) compared with those before treatment, whereas indirect bilirubin levels had no significant difference. CRP and SUA levels were significantly decreased (P<0.05). Compared with the two groups, serum total bilirubin and direct bilirubin levels in the 40 mg/day group were significantly higher than in the 20 mg/day group (P<0.05), but indirect bilirubin levels had no significant difference between groups. CRP and SUA levels in the 40 mg/day group were significantly decreased than in the 20 mg/day group (P<0.05). The rate of change of direct bilirubin was significantly correlated with the level of CRP and SUA. Comared with the two groups, before using atorvastatin, serum total bilirubin in the 40 mg/day group was (10.3±2.0) μmol/L. After treatment it was (13.7±2.2) μmol/L. Direct bilirubin levels before treatment were (3.0±1.1)μmol/L and after treatment were (4.6±1.3)μmol/L. CONCLUSION Atorvastatin calcium in the treatment of CHD can increase the level of serum bilirubin and significantly reduce the levels of CRP and SUA. The higher dose had a more significant effect. The increase of serum bilirubin level was correlated with the decrease of CRP and SUA.

参考文献/References

[1]Moore KJ,Sheedy FJ,Fisher EA. Macrophages in atherosclerosis: adynamic balance[J].Nat Rev Immunol,2013,13(10):709-721.
[2]Davidson MH,Tomassini JE,Jensen E,et al.Changing characteristicsof statin-related cIMT trials from 1988 to 2006[J].Atherosclerosis,2016,246:121-129.
[3]Bedi O,Dhawan V,Sharma PL,et al.Pleiotropic effects of statins:new therapeutic targets in drug design[J].Naunyn Schmiedebergs Arch Pharmacol,2016,389(7):695-712.
[4]Hernández-Díaz Y,Tovilla-Zárate CA,Juárez-Rojop I,et al.The role of gene variants of the inflammatory markers CRP and TNF-α in cardiovascular heart disease:systematic review and meta-analysis.[J].Int J Clin Exp Med,2015,8(8):11958-11984.
[5]Liang WY,Liu WW,Liu ML,et al.Serum uric acid level and left ventricular hypertrophy in elderly male patients with nonvalvular atrial fibrillation[J].Nutr Metab Cardiovasc Dis,2016,26(7):575-580.
[6]Muldoon MF.C-reactive protein and serum amyloid A protein in un-stable angina[J].N Engl J Med,1995,332(6):398-400.
[7]Minnaard MC,van de Pol AC,Hopstaken RM,et al.C-reactive protein point-of-care testing and associated antibiotic prescribing[J].Fam Pract,2016,33(4):408-413.
[8]Devy L,Rabbani SA,Stochl M,et al.PEGylated DX-1000:pharma-cokinetics and antineoplastic activity of a specific plasmin inhibitor[J].Neoplasia,2007,9(11):927-937.
[9]戴晓慧，朱月潜.新诊断高血压患者颈动脉内中膜厚度和C反应蛋白的研究[J].诊断学理论与实践,2011,28(5):89-90.
[10]Lucas AR,Koro lR,Pepine CJ,et al.Inflammation in atherosclero-sis some thoughts about acute coronary syndrome[J].Circulation,2009,113(17):728-732.
[11]Han X,Gui L,Liu B,et al.Associations of the uric acid related genetic variants in SLC2A9 and ABCG2 loci with coronary heart disease risk[J].BMC Genet,2015,16:4.
[12]Ramjee V,Sperling LS,Jacobson TA,et al.Non- high-density lipoprotein cholesterol versus apolipoprotein B in cardiovas-cular risk stratification[J].J Am Coll Cardiol,2011,58(10):457-463.
[13]Zhou ZX,Chen JK,Hong YY,et al.Relationship Between the Serum Total Bilirubin and Inflammation in Patients With Psoriasis Vulgaris[J].J Clin Lab Anal,2016 Apr 7.doi:10.1002/jcla.21936.
[14]Erdogan D,Gullu H,Yildirim E,et al.Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women[J].Atherosclerosis,2006,184(2):431-437.
[15]Idelman G,Smith DL,Zucke SD.Bilirubin inhibits the up-regulation of inducible nitric oxide synthase by scavenging reactive oxygen species generated by the toll-like receptor 4-dependent activation of NADPH oxidase[J].Redox Biol,2015,5:398-408.

备注/Memo

备注/Memo:
收稿日期：2016-07-18.
基金项目：陕西省自然科学基础研究计划(2015JM8468)
通讯作者：冯旭阳，副主任医师，主要从事冠心病发病机制及介入治疗 Email:fengxuyang@sohu.com
共同通讯作者：叶菁，教授，主要从事脂肪代谢研究 Email：yejing@fmmu.edu.cn
作者简介：任彬诚，硕士生 Email:renbincheng7@163.com
更新日期/Last Update: 2016-10-11